Could a Pre-Surgery drug slash recurrence in rare joint tumors?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects aged ≥18 years * Histologically confirmed tenosynovial giant cell tumor (TGCT) * Resectable diffuse tenosynovial giant cell tumor (D-TGCT) were determined by multidisciplinary team (MDT) discussion. * Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 with at least one lesion of ≥2 cm * Symptomatic disease with a worst pain of at least 4 or/and a worst stiffness of at least 4 (based on a scale of 0-10 with 10 describing the worst condition) prior to randomization Adequate organ and bone marrow function * Adequate organ function and bone marrow function * Willing and able to complete patient-reported outcome (PRO) assessments throughout the study. Exclusion Criteria: * Prior treatment with highly selective Colony-Stimulating Factor 1 (CSF1)/ Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitors before randomization * Presence of another malignancy requiring active treatment, in the investigator's judgment, which may interfere with study participation or results * Known metastatic TGCT * Severe concomitant arthropathy, severe illness, or uncontrolled infection in the affected joint * Significant factors affecting oral drug absorption * Concomitant use of strong Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 14 days before randomization * Impaired cardiac function or severe cardiac disease * Known active Human Immunodeficiency Virus (HIV) infection, active hepatitis B, active hepatitis C, or active tuberculosis before randomization * Known active liver or biliary disease, or other conditions that may cause abnormal liver function tests during the study * Pregnant or lactating female (pregnancy defined as from conception until termination) * Fertile males or non-sterilized females who do not agree to use effective contraception from at least 14 days before randomization until 6 months after the last dose of study drug * Other serious comorbidities that, in the investigator's judgment, may affect protocol compliance, interfere with interpretation of study results, or increase the patient's risk of safety events